Single low dose of MPTP decreases extracellular levels of noradrenaline and monoamine metabolites in the ventrobasal thalamus of the rats

Neurobiology (Bp). 1997;5(2):249-61.

Abstract

A single low dose of the neurotoxin: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results paradoxical sleep deprivation and reduction in food intake without any detectable motor deficiencies. In the present study we monitored the in vivo extracellular levels of monoamines and their metabolites following intraperitoneal (i.p.) administration of a single dose of MPTP (5 mg/kg). Microdialysates were collected from the ventrobasal thalamic nucleus (VB) of Halothane anesthetized rat. We found a significant decrease in noradrenaline (NA), 3,4-dihydroxyphenylacetic acid (DOPAC) and 5-hydroxyindoleacetic acid (5-HIAA) levels and a significant increase in 3,4-dihydroxyphenylalanine (DOPA) concentration whereas amino acid levels were unchanged throughout the 4-hour long perfusion. We found no significant difference in the post mortem release of NA and DOPA between the control and MPTP treated animals, suggesting that the intracellular NA pool were maintained. The above findings support the idea that the neurochemical mechanism of rapidly developing and transient behavioral changes induced by MPTP may be an immediate decrease in monoaminergic transmission and metabolism following MPTP injection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / pharmacology*
  • Amino Acids / metabolism
  • Animals
  • Biogenic Monoamines / metabolism*
  • Dopamine Agents / pharmacology*
  • Dose-Response Relationship, Drug
  • Drug Evaluation, Preclinical
  • Norepinephrine / metabolism*
  • Postmortem Changes
  • Rats
  • Thalamic Nuclei / drug effects*
  • Thalamic Nuclei / metabolism

Substances

  • Amino Acids
  • Biogenic Monoamines
  • Dopamine Agents
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Norepinephrine